Altimmune, Inc. (ALT)
Nasdaq · Healthcare · Biotechnology
$2.67−2.38%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $519M
- 52-week range
- $2.56 – $6.44
- 52-week change
- −30.41%
- EPS (trailing)
- −$0.76
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $41K (+105.00%)
- Net income
- −$88.1M
- Operating margin
- −230461.0%
- Diluted EPS
- −$1.00
- Free cash flow
- −$67.5M
From the company’s annual report on SEC EDGAR.
About Altimmune, Inc.
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Headquarters: Gaithersburg, United States · 57 employees · altimmune.com